
Amedisys Inc. (NASDAQ: AMED) was reiterated as Underperform with a $10 price target (versus a $16.91 close) at Credit Suisse.
ARM Holdings PLC (NASDAQ: ARMH) was downgraded to Hold from Buy at Benchmark.
Bank of Nova Scotia (NYSE: BNS) was raised to Outperform from Neutral at Credit Suisse.
Basic Energy Services Inc. (NYSE: BAS) was downgraded to Sell from Hold with a $10 price target at Wunderlich.
Choice Hotels International Inc. (NYSE: CHH) was raised to Neutral from Underperform at Credit Suisse.
Crocs Inc. (NASDAQ: CROX) was downgraded to Neutral from Overweight at Piper Jaffray.
Exelon Corp. (NYSE: EXC) was downgraded to Sell from Neutral with a $26 price target (versus a $27.96 close) at Goldman Sachs.
General Electric Co. (NYSE: GE) was reiterated as Outperform, but the price target was raised to $29 from $27, at Credit Suisse.
Generac Holdings Inc. (NYSE: GNRC) was upgraded to Neutral from Sell at Goldman Sachs.
National Oilwell Varco Inc. (NYSE: NOV) was reiterated as Outperform and the price target was raised to $103 from $89, and it was reiterated as Buy and the price target was raised to $92 from $80 at Sterne Agee.
Public Service Enterprise Group Inc. (NYSE: PEG) was downgraded to Sell from Neutral with a $32 price target (versus a $34.32 close) at Goldman Sachs.
Shoe Carnival Inc. (NASDAQ: SCVL) was downgraded to Neutral from Buy at Sterne Agee.
Sony Corp. (NYSE: SNE) was raised to Outperform from Neutral at Credit Suisse.
Transocean Ltd. (NYSE: RIG) was downgraded to Sell from Neutral with a $50 price target (versus a $49.50 close) at Goldman Sachs.
Veolia Environnement S.A. (NYSE: VE) was downgraded to Underperform from Neutral at Credit Suisse.
Credit Suisse made changes to its US Focus List: Bristol-Myers Squibb Co. (NYSE: BMY) and Vantiv Inc. (NYSE: VNTV) were added, while Automatic Data Processing Inc. (NASDAQ: ADP) and Radian Group Inc. (NYSE: RDN) were removed. The firm ranks Bristol-Myers Squibb as one of the most compelling names in its pharmaceuticals coverage universe as the best positioned to benefit from a multiyear immuno-oncology story. Vantiv is ranked as one of the most compelling names in the data/IT coverage universe.